Show simple item record

dc.contributor.authorMaung, Su W
dc.contributor.authorLeahy, Maeve
dc.contributor.authorO'Leary, Hilary M
dc.contributor.authorKhan, Irfan
dc.contributor.authorCahill, Mary R
dc.contributor.authorGilligan, Oonagh
dc.contributor.authorMurphy, Philip
dc.contributor.authorMcPherson, Suzanne
dc.contributor.authorJackson, Fred
dc.contributor.authorRyan, Mary
dc.contributor.authorHennessy, Brian
dc.contributor.authorMcHugh, Johnny
dc.contributor.authorGoodyer, Matthew
dc.contributor.authorBacon, Larry
dc.contributor.authorO'Gorman, Peter
dc.contributor.authorNee, Aisling
dc.contributor.authorO'Dwyer, Michael
dc.contributor.authorEnright, Helen
dc.contributor.authorSaunders, Jean
dc.contributor.authorO'Keeffe, Denis
dc.date.accessioned2014-07-03T14:05:48Z
dc.date.available2014-07-03T14:05:48Z
dc.date.issued2013-10
dc.identifier.citationA multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. 2013, 163 (1):118-22 Br. J. Haematol.en_GB
dc.identifier.issn1365-2141
dc.identifier.pmid23909468
dc.identifier.doi10.1111/bjh.12486
dc.identifier.urihttp://hdl.handle.net/10147/322351
dc.description.abstractThis retrospective analysis assessed the response, safety and duration of response to standard dose rituximab 375 mg/m(2) weekly for four weeks as therapy for patients with primary or secondary warm autoimmune haemolytic anaemia (WAIHA), who had failed initial treatment. Thirty-four patients received rituximab for WAIHA in seven centres in the Republic of Ireland. The overall response rate was 70·6% (24/34) with 26·5% (9/34) achieving a complete response (CR). The time to response was 1 month post-initiation of rituximab in 87·5% (21/24) and 3 months in 12·5% (3/24) of patients. The median duration of follow-up was 36 months (range 6-90 months). Of the patients who responded, 50% (12/24) relapsed during follow up with a median time to next treatment of 16·5 months (range 6-60 months). Three patients were re-treated with rituximab 375 mg/m2 weekly for four weeks at relapse and responded. There was a single episode of neutropenic sepsis. Rituximab is an effective and safe treatment for WAIHA but a significant number of patients will relapse in the first two years post treatment. Re-treatment was effective in a small number of patients, suggesting that intermittent pulse treatment or maintenance treatment may improve long-term response.
dc.language.isoenen
dc.relation.urlhttp://onlinelibrary.wiley.com/doi/10.1111/bjh.12486/abstracten_GB
dc.rightsArchived with thanks to British journal of haematologyen_GB
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAnemia, Hemolytic, Autoimmune
dc.subject.meshAntibodies, Monoclonal, Murine-Derived
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImmunologic Factors
dc.subject.meshIreland
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshRecurrence
dc.subject.meshRetrospective Studies
dc.subject.meshTreatment Outcome
dc.subject.meshYoung Adult
dc.titleA multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Haematology, University Hospital Limerick, Limerick, Ireland; Department of Haematology, Tallaght Hospital (AMNCH), Dublin, Ireland.en_GB
dc.identifier.journalBritish journal of haematologyen_GB
dc.description.fundingNo fundingen
dc.description.provinceMunsteren
dc.description.peer-reviewpeer-reviewen
html.description.abstractThis retrospective analysis assessed the response, safety and duration of response to standard dose rituximab 375 mg/m(2) weekly for four weeks as therapy for patients with primary or secondary warm autoimmune haemolytic anaemia (WAIHA), who had failed initial treatment. Thirty-four patients received rituximab for WAIHA in seven centres in the Republic of Ireland. The overall response rate was 70·6% (24/34) with 26·5% (9/34) achieving a complete response (CR). The time to response was 1 month post-initiation of rituximab in 87·5% (21/24) and 3 months in 12·5% (3/24) of patients. The median duration of follow-up was 36 months (range 6-90 months). Of the patients who responded, 50% (12/24) relapsed during follow up with a median time to next treatment of 16·5 months (range 6-60 months). Three patients were re-treated with rituximab 375 mg/m2 weekly for four weeks at relapse and responded. There was a single episode of neutropenic sepsis. Rituximab is an effective and safe treatment for WAIHA but a significant number of patients will relapse in the first two years post treatment. Re-treatment was effective in a small number of patients, suggesting that intermittent pulse treatment or maintenance treatment may improve long-term response.


This item appears in the following Collection(s)

Show simple item record